[1]
|
Tang, L., Yao, J., Kong, X., et al. (2017) Increasing Prevalence of Membranous Nephropathy in Patients with Primary Glomerular Diseases: A Cross-Sectional Study in China. Nephrology (Carlton), 22, 168-173.
https://doi.org/10.1111/nep.12739
|
[2]
|
Zhu, P., Zhou, F.D., Wang, S.X., et al. (2015) Increasing Frequency of Id-iopathic Membranous Nephropathy in Primary Glomerular Disease: A 10-Year Renal Biopsy Study from a Single Chi-nese Nephrology Centre. Nephrology (Carlton), 20, 560-566. https://doi.org/10.1111/nep.12542
|
[3]
|
Brglez, V., Boyer-Suavet, S., Zorzi, K., et al. (2020) Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial. Frontiers in Medicine (Lausanne), 7, 412.
https://doi.org/10.3389/fmed.2020.00412
|
[4]
|
Ronco, P. and Debiec, H. (2015) Pathophysiological Advances in Membranous Nephropathy: Time for a Shift in Patient’s Care. The Lancet, 385, 1983-1992. https://doi.org/10.1016/S0140-6736(15)60731-0
|
[5]
|
Lai, W.L., Yeh, T.H., Chen, P.M., et al. (2015) Membranous Nephropathy: A Review on the Pathogenesis, Diagnosis, and Treatment. Journal of the Formosan Medical Association, 114, 102-111.
https://doi.org/10.1016/j.jfma.2014.11.002
|
[6]
|
Ponticelli, C. and Glassock, R.J. (2014) Glomerular Diseases: Membranous Nephropathy—A Modern View. Clinical Journal of the American Society of Nephrology, 9, 609-616. https://doi.org/10.2215/CJN.04160413
|
[7]
|
Polanco, N., Gutiérrez, E., Covarsí, A., et al. (2010) Spontaneous Re-mission of Nephrotic Syndrome in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology, 21, 697-704.
https://doi.org/10.1681/ASN.2009080861
|
[8]
|
王蒙, 王力宁, 刘楠, 等. 血清抗PLA2R抗体水平对特发性膜性肾病的诊断及预后评估[J]. 中国实用内科杂志, 2020, 40(2): 153-157.
|
[9]
|
Subramanyam, M. and Goyal, J. (2016) Translational Biomarkers: From Discovery and Development to Clinical Practice. Drug Discovery Today: Tech-nologies, 21-22, 3-10. https://doi.org/10.1016/j.ddtec.2016.10.001
|
[10]
|
Beck, L.H., Bonegio, R.G., Lambeau, G., et al. (2009) M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy. The New England Journal of Medicine, 361, 11-21.
https://doi.org/10.1056/NEJMoa0810457
|
[11]
|
Hoxha, E., Kneißler, U., Stege, G., et al. (2012) Enhanced Expres-sion of the M-Type Phospholipase A2 Receptor in Glomeruli Correlates with Serum Receptor Antibodies in Primary Membranous Nephropathy. Kidney International, 82, 797-804. https://doi.org/10.1038/ki.2012.209
|
[12]
|
Beck, L.H. and Salant, D.J. (2010) Membranous Nephropathy: Recent Travels and New Roads Ahead. Kidney International, 77, 765-770. https://doi.org/10.1038/ki.2010.34
|
[13]
|
Ronco, P. and Debiec, H. (2014) Anti-Phospholipase A2 Recep-tor Antibodies and the Pathogenesis of Membranous Nephropathy. Nephron Clinical Practice, 128, 232-237. https://doi.org/10.1159/000368588
|
[14]
|
Ronco, P., Plaisier, E. and Debiec, H. (2021) The Role of PLA2R Anti-body Monitoring: What We Know and What We Don’t Know. Nephrology Dialysis Transplantation, gfab356. https://doi.org/10.1093/ndt/gfab356
|
[15]
|
Kdigo (2021) Clinical Practice Guideline for the Management of Glomer-ular Diseases. Kidney International, 100, S1-S276. https://doi.org/10.1016/j.kint.2021.05.021
|
[16]
|
Gunnarsson, I., Schlumberger, W. and Rönnelid, J. (2012) Antibodies to M-Type Phospholipase A2 Receptor (PLA2R) and Membranous Lupus Nephritis. American Journal of Kidney Diseases, 59, 585-586.
https://doi.org/10.1053/j.ajkd.2011.10.044
|
[17]
|
Garcia-Vives, E., Solé, C., Moliné, T., et al. (2019) Antibodies to M-Type Phospholipase A2 Receptor (PLA(2)R) in Membranous Lupus Nephritis. Lupus, 28, 396-405. https://doi.org/10.1177/0961203319828521
|
[18]
|
张雅琪, 郝亚宁, 冯学亮, 等. 单中心特发性膜性肾病发病趋势及与血清PLA_2R抗体的相关性分析[J]. 中华肾脏病杂志, 2016, 32(9): 647-652.
|
[19]
|
庄永泽, 刘敏. 血清抗PLA2R抗体水平与成人特发性膜性肾病临床病理的相关性研究[J]. 中国中西医结合肾病杂志, 2019, 20(12): 1068-1072.
|
[20]
|
Kim, Y.G., Choi, Y.W., Kim, S.Y., et al. (2015) Anti-Phospholipase A2 Receptor Antibody as Prog-nostic Indicator in Idiopathic Membranous Nephropathy. The American Journal of Nephrology, 42, 250-257.
https://doi.org/10.1159/000440983
|
[21]
|
Hoxha, E., Thiele, I., Zahner, G., et al. (2014) Phospholipase A2 Receptor Autoantibodies and Clinical Outcome in Patients with Primary Membranous Nephropathy. Journal of the American Soci-ety of Nephrology, 25, 1357-1366.
https://doi.org/10.1681/ASN.2013040430
|
[22]
|
Hofstra, J.M., Beck, L.H., Beck, D.M., et al. (2011) An-ti-Phospholipase A₂ Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 6, 1286-1291. https://doi.org/10.2215/CJN.07210810
|
[23]
|
Beck, L.H., Fervenza, F.C., Beck, D.M., et al. (2011) Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy. Journal of the American Society of Nephrology, 22, 1543-1550.
https://doi.org/10.1681/ASN.2010111125
|
[24]
|
Segarra-Medrano, A., Jatem-Escalante, E., Carnicer-Cáceres, C., et al. (2014) Evolution of Antibody Titre against the M-Type Phospholipase A2 Receptor and Clinical Response in Idio-pathic Membranous Nephropathy Patients Treated with Tacrolimus. Nefrologia, 34, 491-497.
|
[25]
|
Hoxha, E., Harendza, S., Zahner, G., et al. (2011) An Immunofluorescence Test for Phospholipase-A₂-Receptor Antibodies and Its Clinical Usefulness in Patients with Membranous Glomerulonephritis. Nephrology Dialysis Transplantation, 26, 2526-2532. https://doi.org/10.1093/ndt/gfr247
|
[26]
|
Ruggenenti, P., Fervenza, F.C. and Remuzzi, G. (2017) Treatment of Membranous Nephropathy: Time for a Paradigm Shift. Nature Reviews Nephrology, 13, 563-579. https://doi.org/10.1038/nrneph.2017.92
|
[27]
|
Seitz-Polski, B., Dolla, G., Payré, C., et al. (2016) Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy. Journal of the American Society of Nephrology, 27, 1517-1533.
https://doi.org/10.1681/ASN.2014111061
|
[28]
|
Fresquet, M., Jowitt, T.A., Gummadova, J., et al. (2015) Identifica-tion of a Major Epitope Recognized by PLA2R Autoantibodies in Primary Membranous Nephropathy. Journal of the American Society of Nephrology, 26, 302-313.
https://doi.org/10.1681/ASN.2014050502
|
[29]
|
Cremoni, M., Agbekodo, S., Teisseyre, M., et al. (2022) Toxic Occupational Exposures and Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 17, 1609-1619. https://doi.org/10.2215/CJN.02930322
|
[30]
|
Glassock, R.J. (2014) Antiphospholipase A2 Receptor Autoantibody Guided Diagnosis and Treatment of Membranous Nephropathy: A New Personalized Medical Approach. Clinical Journal of the American Society of Nephrology, 9, 1341-1343. https://doi.org/10.2215/CJN.05880614
|
[31]
|
Seitz-Polski, B., Dahan, K., Debiec, H., et al. (2019) High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 14, 1173-1182.
https://doi.org/10.2215/CJN.11791018
|
[32]
|
Kanigicherla, D., Gummadova, J., Mckenzie, E.A., et al. (2013) An-ti-PLA2R Antibodies Measured by ELISA Predict Long-Term Outcome in a Prevalent Population of Patients with Idio-pathic Membranous Nephropathy. Kidney International, 83, 940-948. https://doi.org/10.1038/ki.2012.486
|
[33]
|
Ruggenenti, P., Debiec, H., Ruggiero, B., et al. (2015) An-ti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. Journal of the American Society of Nephrology, 26, 2545-2558.
https://doi.org/10.1681/ASN.2014070640
|
[34]
|
Chen, Y., Schieppati, A., Cai, G., et al. (2013) Immunosuppression for Membranous Nephropathy: A Systematic Review and Meta-Analysis of 36 Clinical Trials. Clinical Journal of the American Society of Nephrology, 8, 787-796.
https://doi.org/10.2215/CJN.07570712
|
[35]
|
Bech, A.P., Hofstra, J.M., Brenchley, P.E., et al. (2014) Association of Anti-PLA₂R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 9, 1386-1392. https://doi.org/10.2215/CJN.10471013
|